Sandoz Looks To Build U.S. Injectables Business Through Sabex Acquisition
This article was originally published in The Pink Sheet Daily
Executive Summary
The company will add Infufer and hydromorphone injectables in the U.S. following $565 mil. transaction. Sabex makes 89 generic molecules for the Canadian market in its FDA-approved facilities.